Gilead Sciences, Inc. revenue by segment GILD

Annual Quarterly

Gilead Sciences, Inc. splits its revenue into 17 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was HIV Product Sales at $6.2 billion, 75% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	30,988	8,300	7,803	6,960	7,925	7,769	7,082	6,667	7,569
HIV Product Sales	22,772 +11.6% share 73.5%	6,249 +18.4% share 75.3%	5,693 +11.9% share 73.0%	5,030 +9.7% share 72.3%	5,800 +6.4% share 73.2%	5,277 share 67.9%	5,088 share 71.8%	4,587 share 68.8%	5,452 share 72.0%
Oncology Product	3,384 +4.5% share 10.9%	860 +9.1% share 10.4%	—	—	—	788 share 10.1%	—	757 share 11.4%	—
Cell Therapy Products Total Cell Therapy Product Sales	—	—	—	—	—	—	—	—	488 share 6.4%
Trodelvy	—	—	—	402 share 5.8%	384 +8.2% share 4.8%	—	364 share 5.1%	—	355 share 4.7%
Other Products Yescarta	—	—	—	—	368 share 4.6%	—	393 share 5.5%	—	—
Liver Disease Products Vemlidy	—	—	289 share 3.7%	—	287 share 3.6%	—	—	—	—
Other Products Total Other Product Sales	—	—	—	—	—	—	—	—	184 share 2.4%
HIV Products Yeztugo	—	—	—	166 share 2.4%	—	39 share 0.5%	15 share 0.2%	—	—
HIV Products Symtuza Revenue Share	540 +6.7% share 1.7%	132 +6.5% share 1.6%	138 +11.3% share 1.8%	138 +21.1% share 2.0%	133 share 1.7%	124 share 1.6%	124 share 1.8%	114 share 1.7%	—
Liver Disease Products Other Liver Disease	853 +70.6% share 2.8%	117 -7.1% share 1.4%	118 -4.1% share 1.5%	114 -5.8% share 1.6%	—	126 share 1.6%	123 share 1.7%	121 share 1.8%	—
Liver Disease Products Livdelzi	—	—	—	—	—	105 share 1.4%	78 share 1.1%	40 share 0.6%	—
Other Products Am Bisome	465 -7.0% share 1.5%	99 share 1.2%	110 -14.7% share 1.4%	138 -0.7% share 2.0%	118 share 1.5%	—	129 share 1.8%	139 share 2.1%	—
Veklury	464 -55.3% share 1.5%	86 share 1.0%	23 share 0.3%	144 share 2.1%	—	—	—	—	338 share 4.5%
HIV Products Other HIV	455 +23.6% share 1.5%	82 +12.3% share 1.0%	56 share 0.7%	—	190 +69.6% share 2.4%	73 share 0.9%	—	91 share 1.4%	112 share 1.5%
Other Products Other	263 -5.7% share 0.8%	68 +11.5% share 0.8%	51 -30.1% share 0.7%	58 -17.1% share 0.8%	86 +14.7% share 1.1%	61 share 0.8%	73 share 1.0%	70 share 1.0%	75 share 1.0%
Cell Therapy Products Tecartus	296 -15.9% share 1.0%	60 -27.7% share 0.7%	70 share 0.9%	75 -3.8% share 1.1%	90 -8.2% share 1.1%	83 share 1.1%	—	78 share 1.2%	98 share 1.3%
Royalty Contract And Other	223 -58.6% share 0.7%	11 share 0.1%	—	14 -74.1% share 0.2%	22 -33.3% share 0.3%	—	27 share 0.4%	54 share 0.8%	33 share 0.4%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: GILD (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Foster City, CA
SEC filer status: Large accelerated filer
SEC CIK: 882095
Former names: GILEAD SCIENCES INC (until Feb 17, 2022)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.